Skip to main content

Regeneron Pharmaceuticals statistics

  • REGN · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$955.47+0.45%Close 13 Nov 2026

Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.

Valuation

Enterprise value$94.68B
EV / EBITDA17.61
EV / sales5.60

Share price

Latest close$955.47
Day's change+0.4%
52-week high$991.73
52-week low$591.52
From 52-week high−3.7%
Return · 1 month+20.8%
Return · 3 months+15.6%
Return · year to date+23.8%
Return · 1 year+40.2%
Beta · 1 year against the S&P 5000.34
50-day average$816.17
200-day average$746.90
RSI 1468.4
Average volume · 20 sessions1.0M

Margins and returns

For fiscal 2025, as filed.

Operating margin24.9%
Net margin31.4%
Free cash flow margin28.4%
Return on equity14.9%
Return on assets7.9%
Return on invested capital11.5%
Return on capital employed10.2%
Stock-based compensation / revenue6.9%

Financial position

At the end of fiscal 2025.

Cash and equivalents$3.12B
Total debt$2.25B
Net debt−$6.35B
Current ratio4.13
Debt / equity0.07
Net debt / EBITDA−1.54
Interest coverage81.69

Shares and dividends

For fiscal 2025, as filed.

Diluted shares109M
Net share repurchases$2.80B
Dividend payout8.2%

Taxes

For fiscal 2025, as filed.

Income tax expense$725.8M
Effective tax rate13.9%

REGN in the terminal

Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.